6CM
COGT icon

683 Capital Management’s Cogent Biosciences COGT Stock Holding History

683 Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,694
Closed -$92.3K – 163
2023
Q4 		$92.3K Buy
+15,694
New +$120K 0.01% 218

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

683 Capital Management's COGT Position: Q1 2024 in Review

683 Capital Management sold out of Cogent Biosciences (COGT) in Q1 2024, closing a stake of 15,694 shares — an estimated $92.3K sold.

683 Capital Management first reported a position in COGT in Q4 2023 and held it in 1 quarter. The position peaked at $92.3K in Q4 2023. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • 683 Capital Management reported no remaining Cogent Biosciences position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 15,694 Cogent Biosciences shares in Q1 2024, an estimated $92.3K.
  • 683 Capital Management first reported a position in Cogent Biosciences in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Cogent Biosciences position peaked at $92.3K in Q4 2023.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.